Andrew M Scott

Summary

Affiliation: University of Melbourne
Country: Australia

Publications

  1. ncbi request reprint Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial
    A M Scott
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, and Department of Nuclear Medicine and Centre for Positron Emission Tomography, Surgery, and Anatomical Pathology, Melbourne, Australia
    J Clin Oncol 19:3976-87. 2001
  2. ncbi request reprint A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer
    Andrew M Scott
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology, Austin, and Repatriation Medical Centre, 3084 Australia
    Clin Cancer Res 9:1639-47. 2003
  3. ncbi request reprint Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478
    Fook T Lee
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria, Australia
    Clin Cancer Res 11:7080s-7086s. 2005
  4. pmc Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy
    Marcus P Kelly
    Tumour Targeting Laboratory, Ludwig Institute for Cancer Research, Melbourne Centre for ClinicalSciences, Austin Hospital, Heidelberg, Victoria, Australia
    Prostate 69:92-104. 2009
  5. pmc Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct
    Marcus P Kelly
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria, Australia
    Cancer Biother Radiopharm 23:411-23. 2008
  6. ncbi request reprint Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy
    Marcus P Kelly
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria, Australia
    Clin Cancer Res 13:5604s-5612s. 2007
  7. ncbi request reprint Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor
    Terrance G Johns
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg 3084, Australia
    J Biol Chem 279:30375-84. 2004
  8. ncbi request reprint Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model
    Marcus P Kelly
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria 3084, Australia
    J Nucl Med 47:716-25. 2006
  9. doi request reprint Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806
    Fook T Lee
    Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia
    J Nucl Med 51:967-72. 2010
  10. pmc Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice
    Jennifer A Westwood
    Cancer Immunology Program and Department of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, Melbourne, Victoria 3002, Australia
    Proc Natl Acad Sci U S A 102:19051-6. 2005

Research Grants

Detail Information

Publications121 found, 100 shown here

  1. ncbi request reprint Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial
    A M Scott
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, and Department of Nuclear Medicine and Centre for Positron Emission Tomography, Surgery, and Anatomical Pathology, Melbourne, Australia
    J Clin Oncol 19:3976-87. 2001
    ..KM871 is a chimeric monoclonal antibody against the ganglioside antigen GD3, which is highly expressed on melanoma cells. We conducted an open-label, dose escalation phase I trial of KM871 in patients with metastatic melanoma...
  2. ncbi request reprint A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer
    Andrew M Scott
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology, Austin, and Repatriation Medical Centre, 3084 Australia
    Clin Cancer Res 9:1639-47. 2003
    ....
  3. ncbi request reprint Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478
    Fook T Lee
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria, Australia
    Clin Cancer Res 11:7080s-7086s. 2005
    ..This study investigated the effect of EGFR tyrosine kinase inhibition on the efficacy of radioimmunotherapy in a human cancer xenograft model...
  4. pmc Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy
    Marcus P Kelly
    Tumour Targeting Laboratory, Ludwig Institute for Cancer Research, Melbourne Centre for ClinicalSciences, Austin Hospital, Heidelberg, Victoria, Australia
    Prostate 69:92-104. 2009
    ..The ability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 and docetaxel chemotherapy to enhance the efficacy of RIT was also assessed in vivo...
  5. pmc Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct
    Marcus P Kelly
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria, Australia
    Cancer Biother Radiopharm 23:411-23. 2008
    ..However, limited in vitro stability and high renal localization of radiolabeled constructs were observed, which, despite the observed tumor targeting of the hu3S193 multimer, most likely preclude its use in RIT and imaging modalities...
  6. ncbi request reprint Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy
    Marcus P Kelly
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria, Australia
    Clin Cancer Res 13:5604s-5612s. 2007
    ..Therefore, we have investigated the efficacy of the alpha-particle-emitting bismuth-213 (213Bi) radioimmunotherapy using the humanized anti-Lewis Y (Ley) monoclonal antibody humanized 3S193 (hu3S193)...
  7. ncbi request reprint Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor
    Terrance G Johns
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg 3084, Australia
    J Biol Chem 279:30375-84. 2004
    ..Finally, our observations suggest that the generation of antibodies to transitional forms of growth factor receptors may represent a novel way of reducing normal tissue targeting yet retaining antitumor activity...
  8. ncbi request reprint Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model
    Marcus P Kelly
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria 3084, Australia
    J Nucl Med 47:716-25. 2006
    ..The rationale for this combined-modality RIT (CMRIT) was to increase the therapeutic efficacy of RIT through the use of paclitaxel to arrest cells in the radiosensitive G(2)/M phase of the cell cycle...
  9. doi request reprint Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806
    Fook T Lee
    Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia
    J Nucl Med 51:967-72. 2010
    ..The aim of this study was to develop a PET-based method for detecting the constitutively active mutant de2-7 EGFR, which is associated with disease progression and resistance to chemotherapy and radiotherapy in glioma...
  10. pmc Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice
    Jennifer A Westwood
    Cancer Immunology Program and Department of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, Melbourne, Victoria 3002, Australia
    Proc Natl Acad Sci U S A 102:19051-6. 2005
    ..This study supports the use of humanized gene-modified T cells as a potential therapy for Le(Y+) malignancies...
  11. pmc Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody
    Rushika M Perera
    Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria 3084, Australia
    Neoplasia 9:1099-110. 2007
    ..These results highlight the potential use of mAb 806 for generation of conjugates suitable for diagnostic and therapeutic use in patients with EGFR-positive malignancies...
  12. ncbi request reprint The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization
    Terrance G Johns
    Oncogenic Signalling Laboratory and Tumor Targeting Program, Ludwig Institute for Cancer Research, Melbourne Centre, Austin Hospital, Heidelberg, Melbourne, Australia
    Clin Cancer Res 13:1911-25. 2007
    ..Factors affecting the efficacy of therapeutic monoclonal antibodies (mAb) directed to the epidermal growth factor receptor (EGFR) remain relatively unknown, especially in glioma...
  13. pmc A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors
    Andrew M Scott
    Ludwig Institute for Cancer Research, 143 165 Studley Road, Heidelberg, Melbourne, Victoria 3084, Australia
    Proc Natl Acad Sci U S A 104:4071-6. 2007
    ..These in vitro and in vivo characteristics of ch806 distinguish it from all other antibodies targeting EGFR...
  14. pmc A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma
    Ian D Davis
    Ludwig Institute for Cancer Research, Victoria, Australia
    Cancer Immun 7:14. 2007
    ..No antitumour responses were observed. In conclusion, weekly cG250 with daily low-dose subcutaneous IL-2 is well tolerated. IL-2 does not influence cG250 biodistribution or increase HACA...
  15. ncbi request reprint Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft model
    Kiki Tahtis
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Melbourne Branch, Austin, Victoria 3084, Australia
    Mol Cancer Ther 2:729-37. 2003
    ....
  16. ncbi request reprint Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity
    Rushika M Perera
    Ludwig Institute for Cancer Research, Melbourne Branch, Tumor Targeting Program, Austin Hospital, Heidelberg, Victoria, Australia
    Clin Cancer Res 11:6390-9. 2005
    ..Thus, mAb 806 can synergize with other EGFR-specific antibodies thereby providing a rationale for its translation into the clinic...
  17. ncbi request reprint Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma
    Andrew M Scott
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin Hospital, Heidelberg, Victoria, 3084, Australia
    Cancer Immun 5:3. 2005
    ..The favourable immune properties of KM871, combined with this preliminary clinical data, indicate that KM871 has potential for the treatment of metastatic melanoma...
  18. ncbi request reprint The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor
    Terrance G Johns
    Ludwig Institute for Cancer Research, Tumour Targeting Program, Austin Hospital, Heidelberg, Australia
    FASEB J 19:780-2. 2005
    ..As our observations are likely to apply to other receptors overexpressed in cancer, they suggest a strategy for developing antitumor antibodies even when the target receptor is expressed in normal tissue...
  19. doi request reprint MAb 806 enhances the efficacy of ionizing radiation in glioma xenografts expressing the de2-7 epidermal growth factor receptor
    Terrance G Johns
    Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia
    Int J Radiat Oncol Biol Phys 78:572-8. 2010
    ..We have previously shown that mAb 806, a novel EGFR-specific antibody, is able to inhibit the growth of U87MG.Δ2-7 glioma xenografts expressing the de2-7 EGFR and may have potential as a therapeutic...
  20. doi request reprint Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine
    Rebecca A Herbertson
    Ludwig Institute for Cancer Research, Melbourne, Australia
    J Nucl Med 55:534-9. 2014
    ..The primary objective was safety and tolerability of the combination of capecitabine and (131)I-huA33. Pharmacokinetics, biodistribution, immunogenicity, and tumor response were also assessed...
  21. ncbi request reprint A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen
    Andrew M Scott
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin Hospital, Australia
    Clin Cancer Res 13:3286-92. 2007
    ..We report a first-in-man trial of a humanized antibody (hu3S193) against the Le(y) antigen...
  22. ncbi request reprint Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma
    Geoffrey Chong
    Ludwig Institute for Cancer Research, Melbourne, Australia
    Clin Cancer Res 11:4818-26. 2005
    ..Three patients were treated at 20, 30, and 40 mCi/m2 dose levels, and six patients at 50 mCi/m2 to define the maximum tolerated dose...
  23. ncbi request reprint Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871
    Zhanqi Liu
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin and Repatriation Medical Centre, Heidelberg, Victoria, 3084, Australia
    Cancer Immun 2:13. 2002
    ..Furthermore, ADCC was significantly reduced using NK-depleted PBMCs. These results suggest combining IL-2 or IL-12 with KM871 may enhance KM871 immune-mediated cell killing in patients with metastatic melanoma...
  24. doi request reprint Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT
    Nathan Lawrentschuk
    University of Melbourne Department of Surgery, Austin Hospital, Melbourne, Victoria, Australia
    Urol Oncol 29:411-20. 2011
    ....
  25. ncbi request reprint The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR
    Rodney B Luwor
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Melbourne Branch, Austin Hospital, Heidelberg 3084, Australia
    Oncogene 23:6095-104. 2004
    ..This observation is directly relevant to glioma where de2-7 and wt EGFR appear to be coexpressed. Thus, expression of de2-7 EGFR in BaF/3 cells provides an in vitro model for evaluating the signalling pathways activated by this receptor...
  26. doi request reprint Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with 89Zr-DS-8895a
    Ingrid J G Burvenich
    Tumour Targeting Laboratory, Ludwig Institute for Cancer Research and Olivia Newton John Cancer Research Institute, Melbourne, Australia School of Cancer Medicine, La Trobe University, Melbourne, Australia
    J Nucl Med 57:974-80. 2016
    ..This study evaluated the molecular imaging of EphA2 expression in vivo in mouse tumor models using SPECT/MR and PET/MR and a humanized anti-EphA2 antibody, DS-8895a...
  27. pmc Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478
    Terrance G Johns
    Ludwig Institute for Cancer Research, Austin Hospital, Studley Road, Heidelberg 3084, Australia
    Proc Natl Acad Sci U S A 100:15871-6. 2003
    ..These results establish the antitumor efficacy of the EGFR inhibitor AG1478 and provide a rationale for its clinical evaluation in combination with both chemotherapy and other EGFR therapeutics...
  28. pmc A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma
    Ian D Davis
    Ludwig Institute for Cancer Research, Victoria, Australia
    Cancer Immun 7:13. 2007
    ..In conclusion, repeated intravenous doses of up to 50 mg/m(2) of cG250 are safe. Furthermore cG250 has a long half-life and targets clear cell RCC effectively...
  29. pmc The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases
    Vinochani Pillay
    Ludwig Institute for Cancer Research, Heidelberg, Victoria 3084, Australia
    Neoplasia 11:448-58, 2 p following 458. 2009
    ..Consequently, inhibition of a dominant oncogene by targeted therapy can alter the hierarchy of RTKs resulting in rapid therapeutic resistance...
  30. pmc Engineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancers
    Ingrid J G Burvenich
    Tumour Targeting Laboratory, Ludwig Institute for Cancer Research and Olivia Newton John Cancer Research Institute, Melbourne, Vic, Australia
    EJNMMI Res 6:26. 2016
    ..The aim of the study was to explore Fc mutations of a humanised anti-Lewis-Y antibody (IgG1) hu3S193 as a strategy to improve therapeutic ratios for therapeutic payload delivery...
  31. pmc Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization
    Hui K Gan
    Oncogenic Signalling Laboratory, Ludwig Institute for Cancer Research, Austin Health, Heidelberg, Australia
    J Cell Mol Med 13:3993-4001. 2009
    ..Given the increase in VEGF, we combined mAb 806 with bevacizumab in vivo, resulting in additive activity...
  32. doi request reprint Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers
    Rebecca A Herbertson
    Ludwig Institute for Cancer Research, Austin Hospital, Melbourne, Australia
    Clin Cancer Res 15:6709-15. 2009
    ..This phase I study explored the biodistribution and pharmacokinetics of the immunoconjugate CMD-193 [a humanized anti-Lewis Y (Le(y)) antibody conjugated with calicheamicin in patients with advanced cancers expressing the Le(y) antigen...
  33. doi request reprint Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer
    Andrew J Weickhardt
    Ludwig Institute for Cancer Research, Australia
    J Clin Oncol 30:1505-12. 2012
    ..This preclinical and phase II study evaluated the efficacy and safety of the combination of cetuximab and erlotinib in metastatic colorectal cancer (mCRC)...
  34. ncbi request reprint Targeting primary human Ph(+) B-cell precursor leukemia-engrafted SCID mice using radiolabeled anti-CD19 monoclonal antibodies
    Paul Mitchell
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin and Repatriation Medical Centre, Melbourne, Victoria, Australia
    J Nucl Med 44:1105-12. 2003
    ..CD19 is highly expressed (CD19(+)) on ALL cells and is an attractive target for antibody-based therapies. CLB-CD19 is an IgG1kappa murine monoclonal antibody (mAb) directed against an epitope on the CD19 antigen...
  35. ncbi request reprint Generation of anti-idiotype antibodies for application in clinical immunotherapy laboratory analyses
    Zhanqi Liu
    Tumor Targeting Laboratory, Ludwig Institute for Cancer Research, Melbourne Tumor Biology Branch, Austin and Repatriation Medical Centre, 145 164 Studley Road, Heidelberg, Victoria 3084, Australia
    Hybrid Hybridomics 22:219-28. 2003
    ....
  36. doi request reprint Differential and synergistic effects of epidermal growth factor receptor antibodies on unliganded ErbB dimers and oligomers
    Noga Kozer
    Ludwig Institute for Cancer Research, Melbourne Parkville Branch, Royal Melbourne Hospital, Victoria 3050, Australia
    Biochemistry 50:3581-90. 2011
    ..The results reveal new modes of receptor-antibody interactions for EGFR and de2-7-EGFR...
  37. ncbi request reprint A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake
    Andrew M Scott
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Melbourne, Victoria, Australia
    Clin Cancer Res 11:4810-7. 2005
    ..To determine the in vivo characteristics of huA33, a CDR-grafted humanized antibody against the A33 antigen, we have conducted an open-label, dose escalation, biopsy-based phase I trial of huA33 in patients with colorectal carcinoma...
  38. pmc Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism
    Anna N Cvrljevic
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Heidelberg, Victoria 3084, Australia
    J Cell Sci 124:2938-50. 2011
    ..Thus, the mitochondrial localisation of de2-7EGFR contributes to its tumorigenicity and might help to explain its resistance to some EGFR-targeted therapeutics...
  39. doi request reprint Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study
    Andrew M Scott
    Centre for PET, Austin Hospital, Studley Rd, Heidelberg, Melbourne, Victoria 3084, Australia
    Eur J Nucl Med Mol Imaging 36:347-53. 2009
    ..Positron emission tomography (PET) was evaluated in low-grade non-Hodgkin lymphoma (NHL) to determine its impact on staging and management and to compare PET and gallium scans...
  40. pmc In Vitro and In Vivo Evaluation of 89Zr-DS-8273a as a Theranostic for Anti-Death Receptor 5 Therapy
    Ingrid J G Burvenich
    Tumour Targeting Laboratory, Olivia Newton John Cancer Research Institute, Melbourne, Australia School of Cancer Medicine, La Trobe University, Melbourne, Australia
    Theranostics 6:2225-2234. 2016
    ..b>Conclusion:89Zr-Df-Bz-NCS-DS-8273a is a potential novel PET imaging reagent for human bioimaging trials, and can be used for effective dose assessment and patient response evaluation in clinical trials...
  41. pmc Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways
    David W Greening
    Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Australia
    Oncotarget 6:38166-80. 2015
    ....
  42. doi request reprint Global protein profiling reveals anti-EGFR monoclonal antibody 806-modulated proteins in A431 tumor xenografts
    Sze Ting Lee
    Ludwig Institute for Cancer Research, Victoria, Australia
    Growth Factors 31:154-64. 2013
    ....
  43. pmc Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans
    Ian D Davis
    Ludwig Institute for Cancer Research, Melbourne 3084, Australia
    Proc Natl Acad Sci U S A 101:10697-702. 2004
    ..In an unplanned analysis, vaccinated patients appeared to have superior clinical outcomes to those treated with placebo or protein alone. The vaccine is safe and highly potent immunologically...
  44. doi request reprint Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer
    David S Binns
    The Peter MacCallum Cancer Centre, Melbourne, Australia
    Eur J Nucl Med Mol Imaging 38:642-50. 2011
    ..Molecular imaging assessments, including changes in (18)F-deoxyglucose (FDG) or (18)F-deoxythymidine (FLT) uptake by positron emission tomography (PET), may provide earlier, more robust evaluation of treatment efficacy...
  45. ncbi request reprint Assessment of the role of FDG PET in the diagnosis and management of children with refractory epilepsy
    Glenn P Ollenberger
    Department of Nuclear Medicine and Centre for PET, University of Melbourne, Melbourne, Australia
    Eur J Nucl Med Mol Imaging 32:1311-6. 2005
    ..We performed a retrospective analysis of the results of FDG PET scans in children with refractory epilepsy referred to our centre over an 8-year period, with a view to ascertaining the impact of FDG PET on subsequent patient management...
  46. doi request reprint PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study
    Andrew M Scott
    Centre for PET, Austin Hospital, Melbourne, Australia
    J Nucl Med 49:1451-7. 2008
    ..The aims of our study were to examine the impact of PET in changing management in patients with proven or suspected colorectal cancer recurrence and to assess the impact of management change on disease-free survival...
  47. ncbi request reprint Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts
    F T Lee
    Ludwig Institute for Cancer Research, Melbourne Branch, Austin and Repatriation Medical Centre, Studley Road, Heidelberg, Victoria 3084, Australia
    Cancer Res 61:4474-82. 2001
    ..KM871 has potential for targeting tumors in patients with melanoma...
  48. ncbi request reprint Therapeutic targeting of the epidermal growth factor receptor in human cancer
    Nathalie S Dhomen
    Ludwig Institute for Cancer Research, Melbourne, Australia
    Crit Rev Oncog 17:31-50. 2012
    ....
  49. doi request reprint Impact of ¹⁸F-FDG-PET in decision making for liver metastectomy of colorectal cancer
    Andrew R McLeish
    Department of Surgery, University of Melbourne, Austin Hospital, Melbourne, Victoria, Australia
    ANZ J Surg 82:30-5. 2012
    ..However, direct impact of FDG-PET on surgical management of patients with potentially resectable hepatic metastases is limited...
  50. doi request reprint PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a multicenter prospective study
    Andrew M Scott
    Department of Medicine, University of Melbourne, Melbourne, Australia
    J Nucl Med 49:1593-600. 2008
    ..Secondary aims were to determine the incremental staging information provided by PET and to document the effect of PET on treatment outcomes...
  51. doi request reprint The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum
    Jennifer A Westwood
    Cancer Immunology Research Program, Peter MacCallum Cancer Centre, St Andrews Place, Melbourne, Victoria 3002, Australia
    J Immunother 32:292-301. 2009
    ....
  52. pmc Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor
    Ingrid J G Burvenich
    a Tumour Targeting Laboratory, Ludwig Institute for Cancer Research and Olivia Newton John Cancer Research Institute, Melbourne, Vic, Australia
    MAbs 8:775-86. 2016
    ..1 h; wild-type, 163.1 h). These results provide insight into the interaction of human Fc by human FcRn, and are important for antibody-based therapeutics with optimal pharmacokinetics for payload strategies used in the clinic. ..
  53. doi request reprint PET in prostate and bladder tumors
    Sze Ting Lee
    Centre for PET, Austin Hospital, Melbourne, Australia
    Semin Nucl Med 42:231-46. 2012
    ....
  54. doi request reprint Antibodies in oncology
    Vinochani Pillay
    Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria 3084, Australia
    N Biotechnol 28:518-29. 2011
    ..We also discuss the mechanisms of action of anti-cancer mAbs, as well as the antigen targets recognised by these antibodies...
  55. doi request reprint Oncology health information quality on the Internet: a multilingual evaluation
    Nathan Lawrentschuk
    Ludwig Institute for Cancer Research, Austin Hospital, Melbourne, Australia
    Ann Surg Oncol 19:706-13. 2012
    ..We compared the quality of common malignancy Web sites to assess them for language or disease differences and to perform a quality comparison between medical and layperson terminology...
  56. doi request reprint Antibody therapy of cancer
    Andrew M Scott
    Ludwig Institute for Cancer Research University of Melbourne and Centre for PET, Austin Hospital, Melbourne, Victoria 3084, Australia
    Nat Rev Cancer 12:278-87. 2012
    ..This Review outlines the fundamental strategies that are required to develop antibody therapies for cancer patients through iterative approaches to target and antibody selection, extending from preclinical studies to human trials...
  57. ncbi request reprint Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity
    Zhanqi Liu
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Melbourne Branch, Austin and Repatriation Medical Centre, Heidelberg, Victoria 3084, Australia
    Cancer Immunol Immunother 51:171-7. 2002
    ....
  58. ncbi request reprint CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptor
    Francesca Walker
    Ludwig Institute for Cancer Research, PO Royal Melbourne Hospital, Parkville, Victoria 3050, Australia
    J Biol Chem 279:22387-98. 2004
    ....
  59. ncbi request reprint Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO)
    Henri J Tochon-Danguy
    Centre for PET, Austin and Repatriation Medical Centre, 3084, Melbourne, Victoria, Australia
    Nucl Med Biol 29:191-7. 2002
    ..Quantitation of uptake of FMISO showed a tumor/brain ratio of 1.9 and a tumor/blood ratio of 2.6 at 2 hours post injection...
  60. pmc Evaluation of 18 F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer
    Anthony Hannah
    Centre for Positron Emission Tomography, Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia
    Ann Surg 236:208-17. 2002
    ..To prospectively evaluate the use of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in the initial staging of squamous cell head and neck carcinoma...
  61. ncbi request reprint Structural convergence of antibody binding of carbohydrate determinants in Lewis Y tumor antigens
    Paul A Ramsland
    Structural Immunology Laboratory, Austin Research Institute, Heidelberg, VIC 3084, Australia
    J Mol Biol 340:809-18. 2004
    ..Closely related blood-group determinants (Le(a) and Le(b)) cannot enter the specificity pocket, making the Le(y) antibodies promising candidates for immunotherapy of epithelial cancer...
  62. ncbi request reprint Synthesis, 11C labeling and biological properties of derivatives of the tyrphostin AG957
    Uwe Ackermann
    Centre for PET, Austin Health, Heidelberg, VIC 3084, Australia
    Nucl Med Biol 32:323-8. 2005
    ..3+/-2.1% (n=3; not decay corrected) and an average specific radioactivity of 40 GBq/micromol (1.1 Ci/micromol) at the end of synthesis. The total synthesis time from EOB including HPLC purification and formulation was 45 min...
  63. ncbi request reprint Evaluation of geometrical sensitivity for respiratory motion gating by GATE and NCAT simulation
    Jianfeng He
    School of Medical Sciences, RIMT, Australia
    Conf Proc IEEE Eng Med Biol Soc 2007:4165-8. 2007
    ....
  64. doi request reprint Dopamine D(1) receptor binding in the anterior cingulate cortex of patients with obsessive-compulsive disorder
    James S Olver
    Department of Psychiatry, University of Melbourne, Heidelberg, Victoria, Australia
    Psychiatry Res 183:85-8. 2010
    ..These findings suggest mesocortical dopamine inputs via D(1) receptors may play a role in the aetiology of OCD...
  65. ncbi request reprint F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer
    S U Berlangieri
    Department of Nuclear Medicine and Centre for Positron Emission Tomography, Austin and Repatriation Medical Centre, Heidelberg, Australia
    Eur J Cardiothorac Surg 16:S25-30. 1999
    ..The analysis group consists of 50 patients, 37 men and 13 women, mean age 64 years (range, 41-78 years)...
  66. ncbi request reprint Anterior cingulate activation in antipsychotic-naïve first-episode schizophrenia
    M Yucel
    Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne, Melbourne, Carlton South, VIC 3053, Australia
    Acta Psychiatr Scand 115:155-8. 2007
    ..Anterior cingulate (ACC) hypo-activity is commonly observed in chronically ill schizophrenia patients. However, it is unclear whether this is secondary to persistent illness and/or medication...
  67. ncbi request reprint Prevalence of occult metastatic disease in patients undergoing 18F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules
    S T Lee
    Centre for Positron Emission Tomography, and Department of Medicine, University of Melbourne, and Ludwig Institute for Cancer Research, Austin Health, Melbourne, Victoria, Australia
    Intern Med J 37:753-9. 2007
    ..Accurate staging of lung cancer is essential in determining the most appropriate management plan, as detection of occult metastasis can significantly alter management...
  68. doi request reprint Established, emerging and future roles of PET/CT in the management of colorectal cancer
    R A Herbertson
    Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Austin Health, Heidelberg, Victoria, Australia
    Clin Radiol 64:225-37. 2009
    ..The aim of this article is to review the established, emerging, and future roles of FDG-PET/CT in the management of patients with colorectal cancer (CRC)...
  69. doi request reprint Fluorine-18 radiolabeling of a nitrophenyl sulfoxide and its evaluation in an SK-RC-52 model of tumor hypoxia
    Evelyn Laurens
    School of Chemistry, The University of Melbourne, Melbourne, Australia
    J Labelled Comp Radiopharm 59:416-23. 2016
    ..Because of a three times faster clearance rate than [(18) F]FMISO from normoxic tissue, [(18) F]1 has emerged as a promising new radiotracer for hypoxia imaging. ..
  70. doi request reprint Toward hypoxia-selective rhenium and technetium tricarbonyl complexes
    Andrea J North
    Ludwig Institute for Cancer Research, Melbourne Austin Branch, 145 Studley Road, Heidelberg, Victoria 3084, Australia
    Inorg Chem 54:9594-610. 2015
    ..A (99m)Tc tricarbonyl complex with a dipyridylamine ligand bearing a nitroimidazole functional group is stable in human serum and was shown to localize in a human renal cell carcinoma (RCC; SK-RC-52) tumor in a mouse. ..
  71. doi request reprint Current role of PET, CT, MR for invasive bladder cancer
    Nathan Lawrentschuk
    Ludwig Institute for Cancer Research, Melbourne, Australia
    Curr Urol Rep 14:84-9. 2013
    ..This concise review will outline the role of these modalities when dealing with muscle-invasive bladder cancer (MIBC)...
  72. ncbi request reprint Immuno-PET for tumor targeting
    Fook T Lee
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Centre for PET, Austin Hospital, 145 163 Studley Road, Heidelberg, Victoria 3084, Australia
    J Nucl Med 44:1282-3. 2003
  73. ncbi request reprint Detection of occult bone metastases of lung cancer with fluorine-18 fluorodeoxyglucose positron emission tomography
    Serene S Foo
    Department of Nuclear Medicine and Centre for PET, Austin Hospital, Melbourne, Victoria, Australia
    Australas Radiol 48:214-6. 2004
    ..Assessment of glucose metabolism with FDG PET might represent a more powerful tool to detect bone metastases in lung cancer compared with conventional bone scans...
  74. pmc A possible role for metallic ions in the carbohydrate cluster recognition displayed by a Lewis Y specific antibody
    William Farrugia
    Centre for Immunology, Burnet Institute, Melbourne, Victoria, Australia
    PLoS ONE 4:e7777. 2009
    ..A humanized Le(y)-specific antibody (hu3S193) has shown encouraging safety, pharmacokinetic and tumor-targeting properties in recently completed Phase I clinical trials...
  75. pmc Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes
    Paul A Ramsland
    Centre for Immunology, Burnet Institute, Melbourne, Victoria 3004, Australia
    J Immunol 187:3208-17. 2011
    ..A model is presented whereby a dimer of FcγRIIa-HR binds Ag-Ab complexes in an arrangement that possibly occurs on the cell membrane as part of a larger signaling assembly...
  76. ncbi request reprint Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma
    S Ramdave
    Department of Nuclear Medicine and Centre for PET, Department of Nephrology, Oncology Unit, Ludwig Institute for Cancer Research, Austin and Repatriation Medical Centre, Heidelberg, Australia
    J Urol 166:825-30. 2001
    ..FDG-PET may have a role in the diagnostic evaluation of patients with renal cell carcinoma preoperatively and staging of metastatic disease...
  77. doi request reprint Single-chain antibody conjugated to a cage amine chelator and labeled with positron-emitting copper-64 for diagnostic imaging of activated platelets
    Karen Alt
    Vascular Biotechnology Laboratory, Baker IDI, Melbourne, Australia
    Mol Pharm 11:2855-63. 2014
    ..ScFvanti-LIBS-(64)CuMeCOSar is an excellent tool for highly sensitive in vivo detection of activated platelets in PET and has the potential to be used for early diagnosis of acute thrombotic events. ..
  78. doi request reprint Detection of activated platelets in a mouse model of carotid artery thrombosis with 18 F-labeled single-chain antibodies
    Katie Ardipradja
    Vascular Biotechnology Laboratory, Baker IDI, Melbourne, Australia Atherothrombosis and Vascular Biology Laboratory, Baker IDI, Melbourne, Australia Departments of Nuclear Medicine and Centre for PET, Austin Hospital, Melbourne, Australia Department of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia
    Nucl Med Biol 41:229-37. 2014
    ..The aim of this study was the construction and characterisation of a novel (18)F PET radiotracer based on this antibody...
  79. ncbi request reprint Functional imaging of intratumoral hypoxia
    Serene S Foo
    Ludwig Institute for Cancer Research, University of Melbourne, Austin Hospital, Victoria, Australia
    Mol Imaging Biol 6:291-305. 2004
    ..Recent evidence that hypoxia also influences the regulation and transcription of various genes involved in malignant growth and metastases, and promotes a more aggressive tumor phenotype makes its diagnosis even more important...
  80. ncbi request reprint Immuno-PET of human colon xenograft- bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody
    F T Lee
    Melbourne Tumor Biology Branch, Ludwig Institute for Cancer Research, and Centre for PET, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia
    J Nucl Med 42:764-9. 2001
    ..CONCLUSION: In clinical trials using PET, huA33 labeled with 124I has potential for imaging and staging colon tumors and quantifying antibody uptake in colon tumors in vivo...
  81. ncbi request reprint 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy
    L Johns Putra
    Department of Surgery, University of Melbourne, Melbourne, Australia
    Urology 64:1202-7. 2004
    ..To evaluate the role of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) in the assessment of germ cell tumors after chemotherapy...
  82. pmc Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR
    C Panousis
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Level 1, Harold Stokes Building, Austin Hospital, 145 163 Studley Road, Heidelberg 3084, Victoria, Australia
    Br J Cancer 92:1069-77. 2005
    ..These results support a potential therapeutic role of ch806 in the treatment of suitable EGFR-expressing tumours, and warrants further investigation of the potential of ch806 as a therapeutic agent...
  83. ncbi request reprint The expanding role of PET technology in the management of patients with colorectal cancer
    R A Herbertson
    Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Harold Stokes Building, Austin Hospital, Heidelberg, Victoria, Australia
    Ann Oncol 18:1774-81. 2007
    ..This review article aims to discuss the current and future implications of PET technology in the optimal management of CRC patients throughout their care pathway...
  84. pmc Hypoxia-controlled EphA3 marks a human endometrium-derived multipotent mesenchymal stromal cell that supports vascular growth
    Catherine To
    Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Victoria, Australia
    PLoS ONE 9:e112106. 2014
    ....
  85. doi request reprint Sox9 drives columnar differentiation of esophageal squamous epithelium: a possible role in the pathogenesis of Barrett's esophagus
    Nicholas J Clemons
    Surgical Oncology Research Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Am J Physiol Gastrointest Liver Physiol 303:G1335-46. 2012
    ....
  86. doi request reprint Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies
    Eliane Fischer
    Division of Oncology, University Hospital Zurich, Zurich, Switzerland
    Clin Cancer Res 18:6208-18. 2012
    ..We aimed to select novel human-mouse cross-reactive antibodies and to test suitability for tumor therapy as radioimmunoconjugates in a preclinical model...
  87. ncbi request reprint Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene
    Terrance G Johns
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Melbourne, Australia
    Int J Cancer 98:398-408. 2002
    ..Thus, MAb 806 can be used to target tumor cells containing amplification of the EGFR gene or de2-7 EGFR but does not bind to the wild type EGFR when expressed on the cell surface...
  88. ncbi request reprint Radiation dose to PET technologists and strategies to lower occupational exposure
    Fiona O Roberts
    Department of Nuclear Medicine and Centre for PET, Austin Hospital, Melbourne, Australia
    J Nucl Med Technol 33:44-7. 2005
    ..The use of PET in Australia has grown rapidly. We conducted a prospective study of the radiation exposure of technologists working in PET and evaluated the occupational radiation dose after implementation of strategies to lower exposure...
  89. ncbi request reprint Evaluating brain activity in obsessive-compulsive disorder: preliminary insights from a multivariate analysis
    Ben J Harrison
    Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne, Melbourne, Victoria, Australia
    Psychiatry Res 147:227-31. 2006
    ..Implications for the analysis of such studies are discussed...
  90. ncbi request reprint Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3
    M G Achen
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia
    Eur J Biochem 267:2505-15. 2000
    ..The anti-(VEGF-D) mAbs raised to the bioactive region of this growth factor will be powerful tools for analysis of the biological functions of VEGF-D...
  91. ncbi request reprint Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model
    K Tahtis
    Tumor Targeting Program, Ludwig Institute for Cancer Research, Melbourne Branch, Austin and Repatriation Medical Centre, Victoria 3084, Australia
    Clin Cancer Res 7:1061-72. 2001
    ....
  92. ncbi request reprint Current status of positron emission tomography in oncology
    A M Scott
    Centre for Positron Emission Tomography, Ludwig Institute for Cancer Research, Melbourne, Victoria, Australia
    Intern Med J 31:27-36. 2001
    ..PET has the potential to dramatically improve our ability to manage patients with cancer and is also making major contributions to the development of new therapies...
  93. ncbi request reprint Current status of positron emission tomography in oncology
    A M Scott
    Centre for Positron Emission Tomography, Austin and Repatriation Medical Centre and Tumour Targeting Program, Ludwig Institute for Cancer Research, Melbourne, Victoria, Australia
    Australas Radiol 46:154-62. 2002
    ..PET has the potential to dramatically improve our ability to manage patients with cancer and is also making major contributions to the development of new therapies...
  94. ncbi request reprint Positron emission tomography scanning in the assessment of patients with lymphoma
    S S Foo
    Department of Medical Oncology, Ludwig Institute for Cancer Research, University of Melbourne, Austin Hospital, Melbourne, Victoria, Australia
    Intern Med J 34:388-97. 2004
    ....
  95. ncbi request reprint Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR
    R B Luwor
    Ludwig Institute for Cancer Research, Melbourne Branch, Tumour Targeting Program, Austin and Repatriation Medical Centre, Heidelberg 3084, Victoria, Australia
    Cancer Res 61:5355-61. 2001
    ..This study demonstrates that mAb 806 possesses significant antitumor activity...
  96. ncbi request reprint Fluorine-18 fluorothymidine: a new positron emission radioisotope for renal tumors
    Nathan Lawrentschuk
    Department of Surgery, Urology and Medicine, University of Melbourne, Melbourne, Australia
    Clin Nucl Med 31:788-9. 2006
    ..Importantly, the study was able to guide clinicians toward appropriate surgical management. The use of such tracers may herald a new era in renal tumor imaging...
  97. ncbi request reprint Targeted bioactivity of membrane-anchored TNF by an antibody-derived TNF fusion protein
    Stefan Bauer
    Medical Department I, Universitat des Saarlandes, Homburg Saar, Germany
    J Immunol 172:3930-9. 2004
    ..These data warrant transfer of the anti-FAP-TNF immunocytokine into clinical trials for the treatment of FAP-positive tumors...
  98. ncbi request reprint Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer
    Kelvin K Yap
    Centre for PET, University of Melbourne, Austin Hospital Heidelberg, Victoria, 3084, Australia
    Eur J Nucl Med Mol Imaging 32:1033-40. 2005
    ....
  99. ncbi request reprint Impact of 2-deoxy-2[F-18]fluoro-D-glucose Positron Emission Tomography on the management of patients with advanced melanoma
    Marion T Harris
    Centre for Positron Emission Tomography, Austin Hospital, Heidelberg, Victoria, Australia
    Mol Imaging Biol 7:304-8. 2005
    ....
  100. ncbi request reprint Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagents
    Christopher Vearing
    Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia
    Cancer Res 65:6745-54. 2005
    ..These findings show the biological importance of EphA3/ephrin-A5 interactions and that ephrin-A5 and IIIA4 have great potential as tumor targeting reagents...
  101. ncbi request reprint Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography
    Nathan Lawrentschuk
    Department of Surgery, University of Melbourne, Victoria, Australia
    BJU Int 96:540-6. 2005
    ....

Research Grants1

  1. Phase l study of 131 I-HuA33 with oral capecitabine in*
    Andrew Scott; Fiscal Year: 2006
    ..Utilizing a cautious dose escalation protocol, this trial aims to define the maximum tolerated combination of capecitabine and 131l-huA33. [unreadable] [unreadable]..